Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DalCor Pharmaceuticals

www.Dalcorpharma.com

Latest From DalCor Pharmaceuticals

Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

Sales & Earnings Business Strategies

Merck Calls It Quits On Anacetrapib

Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.

Drug Review Research & Development

Merck Calls It Quits On Anacetrapib

Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.

Cardiovascular Clinical Trials

REVEAL: Limited Benefit Leaves Merck & Co Still Undecided On Anacetrapib's Future

The commercial future of Merck & Co's CETP inhibitor anacetrapib is still in limbo as the 9% reduction in the risk of CV events seen in REVEAL underwhelms. Filings look unlikely.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • DalCor Pharmaceuticals
  • Senior Management
  • Robert McNeil, CEO
    Michael Dixon, CFO
    Donald M Black, MD, CMO
    Louise Proulx, PhD, Chief Dev. Officer
  • Contact Info
  • DalCor Pharmaceuticals
    Phone: (514) 564-6474
    Sherbrooke St. West, Ste. 408
    Montreal, H3A 2R7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register